

NIH Eosinophilic Gastroenteritis Research Study

Now enrolling

Dear Support Group,

Doctors at the National Institute of Allergy and Infectious Diseases (National Institutes of Health) are currently conducting a clinical research study involving people with eosinophilic gastroenteritis. The study seeks to investigate omalizumab (anti-IgE, Xolair) in patients with eosinophilic gastroenteritis to determine its safety as well as its ability to decrease blood eosinophil counts and improve disease activity. Omalizumab has been approved by the FDA for use in asthma.

The study takes place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. All study participants receive omalizumab in addition to any standard therapy they were on prior to the study. There is no charge to the patient for therapy, study-related evaluation, or medical tests performed at NIH.

The eligibility criteria for this study include:

- Age 12 and older
- Diagnosis of Eosinophilic Gastroenteritis
- Eosinophil blood count greater than 500
- Evidence of allergy by skin or RAST testing, or serum IgE \geq 100 IU/mL

Contact for referrals:

Please inform your members about this important study. Interested patients should call the NIH Patient Recruitment Office at 1-800-411-1222. We thank you in advance for your help.